

EC initiative on Next Generation sequencing

2nd Symposium : « Introduction of the Next-Generation-sequencing technology in routine analysis in the Belgian healthcare »

Brussels, 7th Novembre 2017

Jean-Luc SANNE, Senior Expert Innovative and personalised medicine Unit, Research & Innovation DG, European Commission jean-luc.sanne@ec.europa.eu



Personalised Medicine: preparing the ground

2010: Preparatory workshops (-omics, biomarkers, clinical trials/regulatory, uptake)

2011: European Perspectives conference

2013: "Omics report"

Identify key challenges to be addressed by research






Personalised medicine – towards a definition

"Personalised medicine refers to a medical model using characterisation of individuals' phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention. Personalised medicine relates to the broader concept of patient-centred care, which takes into account that, in general, healthcare systems need to better respond to patient needs"






Personalised Medicine Conference 2016

1-2 June 2016, Brussels



Circle of the five Challenges







The International Consortium for Personalised Medicine





- A topic under Societal Challenge 1:
- Health, demographic change and wellbeing
- SC1-BHC-10-2019:
- **Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis**
- Pre-Commercial Procurement 16 Apr 2019 40 M€

HORIZON 2020



SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis

Specific Challenge:

- Shift to NGS approach in diagnostics
- NGS allows to consider simultaneously different actionable mutations
- NGS in clinical practice is hampered by various factors: cost, availability of tests, insufficient quality assurance, technological bias and complex interpretation of data.



SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis

Scope:

- Implement NGS in routine diagnostics for personalised medicine and scale up demand-driven innovation for health care systems,
- Include organisational, economical, technical and clinical aspects,
- Consider standards, quality assurance, data issues and Ethics



SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis

Impact:

- New NGS platforms for diagnostics,
- European standards and quality assurance schemes,
- Implementation of personalised medicine,
- Sustainability of healthcare systems
- Benefit to European industry, in particular SMEs




WHY PCP at EU level?

- Support the quality and efficiency of public services with breakthrough solutions.
- Encourage public bodies around Europe to work together on public sector needs.
- Address issues of common European interest, especially where cross-border cooperation can help.
- Support European research activities



PCP to steer the development of solutions towards concrete public sector needs, whilst comparing/validating alternative solution approaches from various vendors

PPI to act as launching customer / early adopter / first buyer of innovative commercial end-solutions newly arriving on the market





PCP Actions (90% funding rate) Provide EU co-financing for an actual PCP procurement (one joint PCP procurement per action) + for related coordination and networking activities (e.g. to prepare, manage and follow-up the PCP call for tender)

Minimum 3 independent participants from 3 different MS or AC, of which minimum 2 public procurers (buyers group) from 2 different MS or AC



Buyers group

- Beneficiaries that provide the financial commitment for procurement.
- Represent the demand side for the innovations, have a critical mass and aim for ambitious quality/efficiency improvements in area of public interest.

Lead procurer

 Public procurer in project appointed by the buyers group to lead and coordinate the procurement,

Subcontractors

- Tenderers selected by the buyers group & lead procurer to provide the R&D services.
- Do 'NOT' enter the grant agreement with the EC.

PCP and PPI actions - What is covered

PCP/PPI actions co-finance (1) + (2)



"ommission

Every project goes through a preparation stage and an execution stage



Commission

Preparation stage

- Open market consultation /verification of market readiness to meet procurement needs,
- Agreed common tender specifications + Joint procurement agreement,
- Financial commitment.

Execution stage

- Joint procurement of the R&D services,
- Follow-up of suppliers and validation of results. Comparison of solution performance to common criteria in real-life conditions,
- Dissemination/exploitation of results,

Other activities (e.g. preparation of follow-up PPI, contribution to standardisation / regulation / certification)



□ Direct costs: Max 90% of eligible costs for PCP

- Eligible costs include:
 - Price of R&D services procured,
 - Eligible coordination and networking activities,
 - In-kind contributions (e.g. third parties making resources available for testing of solutions)
 - VAT is eligible if not deductible,
- Coordination and networking activities: max 30% of total requested grant.

Plus 25% for indirect costs

Excluded: procurement price or on 3rd party resources not used on beneficiary premises

Pre-financing (1st at start, 2nd before execution)



In the proposal, the consortium shall already identify

- A concrete 'common challenge' on which the procurement will focus
- Key Performance Indicators (targeted quality/efficiency improvements)
- How this challenge fits in the innovation strategy / plans of the participating procurers

One joint call for tender published EU wide

One joint evaluation of offers based on common tender specs

 One lead procurer awarding all contracts in the name and on behalf of all procurers in buyers group
One joint total budget (grouping financial commitments of all procurers in buyers group) from which all R&D providers are paid





www.ec.europa.eu/research/health www.ec.europa.eu/research/horizon2020

